[go: up one dir, main page]

WO2011072208A1 - Composés sensibles au ph destinés à masquer le goût de bandelettes orales sous forme de film mince - Google Patents

Composés sensibles au ph destinés à masquer le goût de bandelettes orales sous forme de film mince Download PDF

Info

Publication number
WO2011072208A1
WO2011072208A1 PCT/US2010/059851 US2010059851W WO2011072208A1 WO 2011072208 A1 WO2011072208 A1 WO 2011072208A1 US 2010059851 W US2010059851 W US 2010059851W WO 2011072208 A1 WO2011072208 A1 WO 2011072208A1
Authority
WO
WIPO (PCT)
Prior art keywords
water
dosage form
active
edible film
film
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/059851
Other languages
English (en)
Inventor
A. Mark Schobel
Kevin Davidson
Laura Miloshoff
Pradeep Sanghvi
Madhu Hariharan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aquestive Therapeutics Inc
Original Assignee
MonoSol Rx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MonoSol Rx LLC filed Critical MonoSol Rx LLC
Priority to CA2783877A priority Critical patent/CA2783877A1/fr
Priority to CN2010800634577A priority patent/CN102753196A/zh
Priority to EP10836740.0A priority patent/EP2509631A4/fr
Publication of WO2011072208A1 publication Critical patent/WO2011072208A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Definitions

  • the present invention relates to compositions relating to films containing active pharmaceutical agents.
  • the invention more particularly relates to self-supporting dosage forms that include active components and pH sensitive components, which provide taste- masking for the active components. Some embodiments also include multiple coating layers of pH sensitive components.
  • active agents such as pharmaceutical preparations may be included in a tablet or similar form to provide an accurate and consistent dose, such a form has several
  • a film composition including: (i) a film- forming polymer; and (ii) an active composition including a granulated particle comprising at least one active selected from pharmaceutical agents, bioeffecting agents, bioactive agents, cosmeceuticals, nutraceuticals, vitamins, antigens, and such other actives, and combinations thereof, and a coating composition at least partially coating the active, said coating including a taste-masking effective amount of a reverse-enteric polymer composition and a water-insoluble polymeric composition, where the reverse-enteric polymer composition and the water-insoluble polymeric composition are present in an amount of about 9: 1 to about 1 :9 by weight of the coating composition and the at least partially coated active component is substantially water-insoluble at a neutral pH.
  • an edible film for delivery of an active including, an edible film dosage form including: (a) an edible, water-soluble film forming polymer; and (b) an active composition including: (i) an active component selected from cosmetic agents, pharmaceutical agents, vitamins, antigens, bioactive agents, bioeffecting agents and combinations thereof; (ii) a first coating layer substantially surrounding the active component; and (iii) a second coating layer substantially surrounding the first coating layer; where the edible film dosage form is self-supporting.
  • the present invention provides a therapeutic film composition film for ingestion or topical administration, including a composition having a uniformly distributed combination of a polymer, a polar solvent, and a taste-masked active ingredient.
  • the composition in its dried film form maintains the uniform distribution of components of which it was formed.
  • the therapeutic film dosage composition preferably includes a polymeric carrier matrix. Any desired polymeric carrier matrix may be used, provided that it is orally dissolvable and is suitable for use with humans, i.e., ingestion, implantation or topical use.
  • the films are designed to dissolve when placed in contact with mucosal fluids, such as saliva, but the taste-masked active coating remains undissolved in order to protect the active and to prevent the user from detecting the taste of the active. Rapid release, controlled and sustained release compositions are among the various embodiments contemplated.
  • the film products of the invention may be produced by forming a matrix comprising at least one film- forming polymer and a polar solvent, optionally including other fillers known in the art.
  • the active composition may be added during formation of the matrix, but is desirably added after the matrix is prepared to prevent the active from over exposure to the solvent.
  • the solvent may be water, a polar organic solvent including, but not limited to, ethanol, isopropanol, acetone, methylene chloride, or any combination thereof.
  • the composition may employ little or no solvent, such as when hot melt extrusion processes are used.
  • the film may be prepared by utilizing a casting or deposition methods and a controlled drying process or by various extrusion methods including hot melt extrusion.
  • the film may be prepared through controlled drying processes, which include application of heat and/or radiation energy to the wet film matrix to form a visco-elastic structure, thereby controlling the uniformity of content of the film.
  • controlled drying processes include application of heat and/or radiation energy to the wet film matrix to form a visco-elastic structure, thereby controlling the uniformity of content of the film.
  • the films may be extruded as described in commonly assigned U.S. Application No. 10/856,176, filed on May 28, 2004, and published as U.S. Patent Publication No. 2005/0037055 Al, the contents of which are incorporated herein by reference in their entirety.
  • the drying process locks-in the content uniformity of the film by forming a visco-elastic matrix with the first 4 to 10 minutes of drying.
  • the polymers that form the matrix of the film may be water-soluble, water- swellable, water-insoluble, or a combination of one or more either water-soluble, water-swellable or water-insoluble polymers.
  • the polymer may include cellulose or a cellulose derivative.
  • useful water-soluble polymers include, but are not limited to, polyethylene oxide, pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers, starch, gelatin, and combinations thereof.
  • useful water-insoluble polymers include, but are not limited to, ethyl cellulose,
  • hydroxypropyl ethyl cellulose cellulose acetate phthalate, cellulose acetate, hydroxypropyl methyl cellulose phthalate and combinations thereof.
  • water-soluble polymer and variants thereof refer to a polymer that is at least partially soluble in water, and desirably fully or predominantly soluble in water, or absorbs water. Polymers that absorb water are often referred to as being water- swellable polymers.
  • the materials useful with the present invention may be water-soluble or water-swellable at room temperature and other temperatures, such as temperatures exceeding room temperature. Moreover, the materials may be water-soluble or water-swellable at pressures less than atmospheric pressure. Desirably, the water-soluble polymers are water- soluble or water-swellable having at least 20 percent by weight water uptake. Water- swellable polymers having a 25 or greater percent by weight water uptake are also useful.
  • films formed from such water-soluble polymers may be sufficiently water-soluble to be dissolvable upon contact with bodily fluids.
  • film-forming polymers useful for incorporation into the films include biodegradable polymers, copolymers, block polymers and combinations thereof.
  • biodegradable polymers include biodegradable polymers, copolymers, block polymers and combinations thereof.
  • known useful polymers or polymer classes which meet the above criteria are: poly(glycolic acid) (PGA), poly(lactic acid) (PLA), polydioxanoes, polyoxalates, poly(a-esters), polyanhydrides, polyacetates, polycaprolactones, poly(orthoesters), polyamino acids, polyaminocarbonates, polyurethanes, polycarbonates, polyamides, poly(alkyl)
  • Additional useful polymers include, stereopolymers of L- and D-lactic acid, copolymers of bis(p-carboxyphenoxy) propane acid and sebacic acid, sebacic acid copolymers, copolymers of caprolactone, poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, copolymers of polyurethane and (poly(lactic acid), copolymers of polyurethane and poly(lactic acid), copolymers of a-amino acids, copolymers of a-amino acids and caproic acid, copolymers of a-benzyl glutamate and polyethylene glycol, copolymers of succinate and poly(glycols), polyphosphazene, polyhydroxy-alkanoates and mixtures thereof.
  • Binary and ternary systems are contemplated.
  • lactide/glycolide 85/15 believed to be 85% lactide and 15% glycolide with a melting point within the range of 338°-347°F (170°-175° C); and lactide/glycolide 50/50, believed to be a copolymer of 50% lactide and 50% glycolide with a melting point within the range of 338°- 347°F (170°-175°C).
  • the Biodel materials represent a family of various polyanhydrides which differ chemically.
  • the time period for which it is desired to maintain the film in contact with the mucosal tissue depends on the type of active contained in the second delivery vehicle. Some actives may only require a few minutes for delivery through the mucosal tissue, whereas other actives may require up to several hours or even longer.
  • one or more water-soluble polymers may be used to form the film.
  • the inclusion of one or more polymers that are water-swellable, water-insoluble and/or biodegradable may provide films with slower dissolution or disintegration rates than films formed from water-soluble polymers alone.
  • the film may adhere to the mucosal tissue for longer periods or time, such as up to several hours, which may be desirable for delivery of certain active components.
  • Oral dissolving films may be defined as falling into three main classes: fast dissolving, moderately slow dissolving and slow dissolving.
  • Fast dissolving films generally dissolve in about 1 second to about 30 seconds.
  • Moderately slow dissolving films generally dissolve in about 1 to about 30 minutes, and slow dissolving films generally dissolve in more than 30 minutes.
  • Fast dissolving films may consist of low molecular weight hydrophilic polymers (i.e., polymers having a molecular weight between about 1,000 to 9,000).
  • slow dissolving films generally have high molecular weight polymers (i.e., having a molecular weight in the millions).
  • Moderately slow dissolving films tend to fall in between the fast and slow dissolving films.
  • Moderate dissolving films dissolve rather quickly, but also have a good level of mucoadhesion.
  • Moderate films are also flexible, quickly wettable, and are typically non- irritating to the user.
  • the individual film dosage has a small size, which is between about 0.5-1 inch by about 0.25-1.5 inch. Most preferably, the film dosage is about 0.75 inches by about 0.5 inches.
  • the film dosage should have good adhesion when placed in the buccal cavity or in the sublingual region of the user. Further, the film dosage should disperse and dissolve at a moderate rate, that is, between about 1 minute to about 30 minutes, and most desirably between about 10 minutes and about 20 minutes. In some embodiments, however, it may be desired to allow the individual film dosage to dissolve slower, over a period of longer than about 30 minutes. In such slow dissolving embodiments, it is preferable that the film dosage has strong mucoadhesion properties. Sublingual and buccal films are contemplated and the size and thickness as well as the specific taste-masking composition and film matrix composition may be tailored to achieve the desired dissolution rate and time.
  • the polymer may be water soluble, water swellable, water insoluble or a combination of one or more either water soluble, water swellable or water insoluble polymers.
  • the polymer may include cellulose or a cellulose derivative.
  • Specific examples of useful water soluble polymers include, but are not limited to, polyethylene oxide (PEO), pullulan, hydroxypropylmethyl cellulose (HPMC), hydroxyethyl cellulose (HPC), hydroxypropyl cellulose, polydextrose, polyvinyl pyrrolidone, copolyvidone (vinylpyrrolidone/vinyl acetate copolymer), carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, propylene glycol alginate, carrageenan, polyethylene glycol, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, poloxamer polymers, copolymers
  • carboxyvinyl copolymers starch, gelatin, pectin, and combinations thereof.
  • water soluble polymer and variants thereof refer to a polymer that is at least partially soluble in water, and desirably fully or predominantly soluble in water, or absorbs water. Polymers that absorb water are often referred to as being water swellable polymers.
  • the materials useful with the present invention may be water soluble or water swellable at room temperature and other temperatures, such as temperatures exceeding room temperature. Moreover, the materials may be water soluble or water swellable at pressures less than atmospheric pressure. Desirably, the water soluble polymers are water soluble or water swellable having at least 20 percent by weight water uptake. Water swellable polymers having a 25 or greater percent by weight water uptake are also useful.
  • Films or dosage forms of the present invention formed from such water soluble polymers are desirably sufficiently water soluble to be dissolvable upon contact with bodily fluids.
  • water insoluble polymers include, but are not limited to, ethyl cellulose, hydroxypropyl ethyl cellulose, cellulose acetate phthalate, cellulose acetate, hydroxypropyl methyl cellulose phthalate, polyvinyl acetate phthalate, acrylic polymers, vinyl acetate, sodium sulphonated polyesters, carboxylated acrylics,
  • trimethylpentanediol/adipic acid/glycerin cross polymer polyglycerol-2-diisostearate/IPDI copolymer, carboxylated vinyl acetate copolymer, vinylpyrrolicone/vinyl
  • polymers useful for incorporation into the films of the present invention include biodegradable polymers, copolymers, block polymers and combinations thereof.
  • biodegradable polymers include biodegradable polymers, copolymers, block polymers and combinations thereof.
  • PLA poly(lactic acid)
  • PLA poly(lactic acid)
  • PDA polydioxanoes, polyoxalates
  • poly(a-esters) polyanhydrides
  • polyacetates polycaprolactones
  • poly(orthoesters) polyamino acids
  • polyaminocarbonates polyurethanes
  • polycarbonates polyamides
  • poly(alkyl) poly(alkyl)
  • Additional useful polymers include, stereopolymers of L- and D-lactic acid, copolymers of bis(p-carboxyphenoxy) propane acid and sebacic acid, sebacic acid copolymers, copolymers of caprolactone, poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, copolymers of polyurethane and (poly(lactic acid), copolymers of polyurethane and poly(lactic acid), copolymers of a-amino acids, copolymers of a-amino acids and caproic acid, copolymers of a-benzyl glutamate and polyethylene glycol, copolymers of succinate and poly(glycols), polyphosphazene, polyhydroxy-alkanoates and mixtures thereof.
  • Binary and ternary systems are contemplated.
  • lactide/glycolide 85/15 believed to be 85% lactide and 15% glycolide with a melting point within the range of 338°-347°F (170°-175° C); and lactide/glycolide 50/50, believed to be a copolymer of 50% lactide and 50% glycolide with a melting point within the range of 338°- 347°F (170°-175°C).
  • the Biodel materials represent a family of various polyanhydrides which differ chemically. Although a variety of different polymers may be used, it is desired to select polymers to provide a desired viscosity of the mixture prior to drying. For example, if the active or other components are not soluble in the selected solvent, a polymer that will provide a greater viscosity is desired to assist in maintaining uniformity. On the other hand, if the components are soluble in the solvent, a polymer that provides a lower viscosity may be preferred. The polymer plays an important role in affecting the viscosity of the film. Viscosity is one property of a liquid that controls the stability of the active in an emulsion, a colloid or a suspension.
  • the viscosity of the matrix will vary from about 400 cps to about 100,000 cps, preferably from about 800 cps to about 60,000 cps, and most preferably from about 1,000 cps to about 40,000 cps. Desirably, the viscosity of the film-forming matrix will rapidly increase upon initiation of the drying process.
  • the viscosity may be adjusted based on the selected active depending on the other components within the matrix. For example, if the component is not soluble within the selected solvent, a proper viscosity may be selected to prevent the component from settling which would adversely affect the uniformity of the resulting film.
  • the viscosity may be adjusted in different ways.
  • the polymer may be chosen of a higher molecular weight or crosslinkers may be added, such as salts of calcium, sodium and potassium.
  • the viscosity may also be adjusted by adjusting the temperature or by adding a viscosity increasing component.
  • Components that will increase the viscosity or stabilize the emulsion/suspension include higher molecular weight polymers and
  • polysaccharides and gums which include without limitation, alginate, carrageenan, hydroxypropyl methyl cellulose, locust bean gum, guar gum, xanthan gum, dextran, gum arabic, gellan gum and combinations thereof. Further adjustments may be made by changing the concentration of polymer used in the formulation or changing the total percentage of solids used in the formulation. It has also been observed that certain polymers which when used alone would ordinarily require a plasticizer to achieve a flexible film, can be combined without a plasticizer and yet achieve flexible films. For example, HPMC or HPC when used in combination with PEO provide a flexible, strong film with the appropriate plasticity and elasticity for manufacturing and storage. No additional plasticizer or polyalcohol is needed for flexibility.
  • polyethylene oxide when used alone or in combination with at least one additional polymer, achieves flexible, strong films. Additional plasticizers or polyalcohols are not needed for flexibility.
  • suitable cellulosic polymers for combination with PEO include HPC and HPMC. PEO and HPC have essentially no gelation temperature, while HPMC has a gelation temperature of 58-64°C (Methocel EF available from Dow Chemical Co.).
  • HPC has essentially no gelation temperature
  • HPMC has a gelation temperature of 58-64°C (Methocel EF available from Dow Chemical Co.).
  • these films are sufficiently flexible even when substantially free of organic solvents, which may be removed without compromising film properties. As such, if there is no solvent present, then there is no plasticizer in the films.
  • PEO based films also exhibit good resistance to tearing, little or no curling, and fast dissolution rates when the polymer component contains appropriate levels of PEO.
  • the level and/or molecular weight of PEO in the polymer component may be varied. Modifying the PEO content affects properties such as tear resistance, dissolution rate, and adhesion tendencies.
  • one method for controlling film properties is to modify the PEO content. For instance, in some embodiments rapid dissolving films are desirable. By modifying the content of the PEO polymer component, the desired dissolution characteristics can be achieved.
  • PEO desirably ranges from about 5% to about 100% by weight in the polymer component, more specifically in the amount of about 20%) to about 100%) by weight, even more specifically, in the amount of about 30%> to about 70% by weight. In some embodiments, the PEO is present in the amount of about 40% to about 60% by weight of the polymer component. In some embodiments, the amount of PEO desirably ranges from about lmg to about 200mg.
  • the hydrophilic cellulosic polymer ranges from about 0%> to about 80%> by weight, more specifically, in the amount of about 30%> to about 70%) by weight, even more specifically, from about 40%> to about 60%> by weight of the polymer component, or in a ratio of up to about 4: 1 with the PEO, and desirably in a ratio of about 1 : 1.
  • PEO levels it may be desirable to vary the PEO levels to promote certain film properties.
  • levels of about 50% or greater of PEO in the polymer component are desirable.
  • PEO levels of about 20%) to 75%o are desirable.
  • adhesion to the roof of the mouth may be desired, such as for administration to animals or children.
  • higher levels of PEO may be employed. More specifically, structural integrity and dissolution of the film can be controlled such that the film can adhere to mucosa and be readily removed, or adhere more firmly and be difficult to remove, depending on the intended use.
  • the molecular weight of the PEO may also be varied.
  • High molecular weight PEO such as about 4 million, may be desired to increase mucoadhesiveness of the film. More desirably, the molecular weight may range from about 100,000 to 900,000, more desirably from about 100,000 to 600,000, and most desirably from about 100,000 to 300,000. In some embodiments, it may be desirable to combine high molecular weight (600,000 to 900,000) with low molecular weight (100,000 to 300,000) PEOs in the polymer component. For instance, certain film properties, such as fast dissolution rates and high tear resistance, may be attained by combining small amounts of high molecular weight PEOs with larger amounts of lower molecular weight PEOs. Desirably, such compositions contain about 60% or greater levels of the lower molecular weight PEO in the PEO-blend polymer component.
  • desirable film compositions may include about 50% to 75% low molecular weight PEO, optionally combined with a small amount of a higher molecular weight PEO, with the remainder of the polymer component containing a hydrophilic cellulosic polymer (HPC or HPMC).
  • HPC hydrophilic cellulosic polymer
  • the film may include polyvinyl alcohol (PVA), alone or in combination with at least one additional polymer.
  • additional polymer include a cellulosic polymer, starch, polyvinyl pyrrolidone (PVP), polyethylene oxide (PEO), an alginate, a pectin, or combinations thereof.
  • PVA can be used in the films to improve film strength and/or to vary and slow dissolution times.
  • the films are especially useful for the delivery of cosmetics, nutraceuticals and pharmaceuticals.
  • the film includes PVA without any added platicizers.
  • the film can include both PVA, which provides strength to the film and PEO, which provides flexibility to the film and may obviate the need for a plasticizer.
  • PVA can be used in varying amounts depending upon the product application and characteristics desired. For example, in general, a larger amount of PVA will increase film strength and increase dissolution time. For films that require high active dosing, PVA can be used effectively at minimum amount of 0.5, preferably 1%, more preferably 5%, by weight of the film, to improve film strength. The PVA can be effectively used at a maximum amount of, for example, 80%, preferably 50%, more preferably 25% by weight of the film. For slowing dissolution time, PVA can be used at levels as high as 80%>. A film containing an active can be coated on one or both surfaces with a PVA containing layer to modify the dissolution of the film and the release of an active from the film.
  • High loading of actives can decrease the strength and flexibility of the film.
  • Including PVA in the film either alone or in combination with at least one other polymer can increase the tensile strength of the film.
  • drug particles or taste-masked or coated or modified release drug particles may have a larger particle size, which can make loading of these particles into the film difficult.
  • PVA can increase the viscosity of the film solution to allow improved drug loading.
  • the films may include a coated active composition to provide a taste masking of the active component.
  • the films may include ionic exchange resins, including but not limited to a water-insoluble organic or inorganic matrix material having covalently bound functional groups that are ionic or capable of being ionized under appropriate conditions.
  • the organic matrix may be synthetic (e.g., polymers or copolymers or acrylic acid, methacrylic acid, sulfonated styrene or sulfonated divinylbenzene) or partially synthetic (e.g., modified cellulose or dextrans).
  • the inorganic matrix may be, for example, silica gel modified by the addition of ionic groups. Most ion exchange resins are cross-linked by a crosslinking agent, such as divinylbenzene.
  • the coated active composition may include a taste-masking effective amount of a reverse-enteric polymer and a water-insoluble polymeric composition.
  • reverse- enteric polymers may include copolymers of dimethyl aminoethyl methacrylate and neutral methacrylic acid esters, such as Eudragit ® E-100 as sold by Evonik Industries and water- insoluble, pH independent base polymeric constituent, such as cellulose acetate or ethylcellulose, applied from an organic solution, such as acetone, on to the drug particles or granules in a fluid bed dryer using a top-spray, bottom-spray or Wurster column bottom spray configuration.
  • water-insoluble polymers may include any as discussed above.
  • the relative portion of dimethyl aminoethyl methacrylate and neutral methacrylic acid esters to cellulose acetate may be in the range of about 9: 1 to about 1 :9. In some
  • the ratio may be in the range of about 4: 1 to about 1 :4. In other embodiments, the ratio may be the range of about 2: 1 to about 1 :2. In other embodiments, the ratio may be about 1 : 1. More typically, a range of 3:7 to about 7:3. In some embodiments, 100% E-100 can also be used. The actual ratio used depends on the degree of taste-masking required as well as the rate at which drug release is desired under acidic, neutral or basic conditions. In addition, the rate may vary depending on the solubility and other characteristics of the API being taste-masked.
  • the taste-masking coating may avoid or minimize the release of the drug from the particle in the manufacturing process of the oral thin film as well as within the neutral or near-neutral environment presented by the saliva of the oral cavity when the oral thin film containing the drug particle is administered to the consumer.
  • the insoluble cellulose acetate along with the conditionally soluble reverse-enteric polymer in the coating serves as a barrier to water during manufacturing and as a barrier to saliva during consumption of the dosage form by the consumer.
  • the reverse enteric polymer dissolves to form pores in the overall coating structure thereby allowing the diffusion of drug out of the particle to be absorbed in the gastrointestinal tract.
  • excipients may be added to the coating composition to further increase the rate of release of the drug from the film. Desirably, the taste-masking properties are still maintained after the addition of these excipients.
  • an acid-reactive material such as calcium carbonate or calcium phosphate.
  • other acid-reactive materials e.g., bases, may be employed to maintain the pH at levels which promote insolubility in the mouth, yet are readily soluble in acid pH once fully ingested.
  • Some of the useful taste-mask coating materials may swell in water regardless of the pH.
  • Eudragit ® E-100 a polyacrylate polymer
  • Such water absorption and swelling of the polymer enhances the risk of the active to diffuse through the coating and which would defeat the taste -masking effect.
  • One aspect of the invention includes a means to minimize diffusion of the drug through the coating, thereby preventing the perception of a bad-tasting active. This can be achieved by adjusting the ratio of the polymers in the coating. While adjusting the ratio of the polymers in the coating can be used to minimize the risk of active diffusing therethrough, the dissolution rate in the stomach may be lengthened as a result. This problem may be solved through the incorporation of water-insoluble, acid-reactive materials such as calcium carbonate, incorporated into the taste-masking composition.
  • the acid-reactive material is unreactive and insoluble.
  • the acid-reactive material e.g., calcium carbonate would react with gastric acid to liberate carbon dioxide.
  • the effervescing action of the carbon dioxide selectively disrupts the coating layer in the presence of stomach acid and facilitates dissolution, release and absorption of the active.
  • Particle size of the acid-reactive material also plays a role in facilitating coating disruption.
  • calcium carbonate may have a larger reactive surface area and produce higher amounts of carbon dioxide, thus enhancing disruption of the coating.
  • the particle size of the acid-reactive material e.g., calcium carbonate, may be from about 0.5 um to about 25 um. In some embodiments, in some embodiments, the particle size may be from about 1.0 um to about 15 um. In some embodiments, particles may range from 1 um to 10 um. In some embodiments, the particle size may be from about 5.0 um to about 10 um. Acid-reactive materials may be used in the granulation process, taste-masking process or both.
  • the oral thin film may include non-pH dependent materials such as sucrose, natural sweeteners or artificial sweeteners, surfactants, fillers, coloring agents, flavors, disintegrating agents, salts and other non-pH dependent materials,
  • non-pH dependent materials such as sucrose, natural sweeteners or artificial sweeteners, surfactants, fillers, coloring agents, flavors, disintegrating agents, salts and other non-pH dependent materials,
  • the non-pH dependent materials may be released as the polymer layer is increasingly hydrated and swells. This further increases the permeability of the coating by forming contiguous channels within the coating through which the drug can diffuse out of the particulate core.
  • insoluble and hydrophobic materials may be added to the polymer composition in the taste-masking layer to help in making the particle hydrophobic and resist penetration by water during manufacturing.
  • Such components may have the added benefit of improving processiblity during fluid bed coating by alleviating the build-up of electrostatic charges which may cause improper application of the coating on the particles.
  • compounds that may be used in this capacity may include magnesium stearate, stearic acid, sodium stearyl fumarate or talc, silicon dioxide and combinations thereof.
  • Plasticizers such as triacetin, dibutyl sebacate and triethyl citrate and diethyl phthalate may also be added to improve the properties of the taste masking coating.
  • a two-layered film approach is provided to further improve the functionality of the reverse-enteric polymer coating system for taste-masking.
  • the finished coated particle may be dispersed in an aqueous polymer solution to be cast into oral thin films.
  • the coated particle may then be exposed to water in an aqueous polymer solution during the manufacturing process for up to an hour, or more.
  • the reverse-enteric polymer may retain its integrity but will absorb water and swell.
  • Certain therapeutic actives such as pharmaceutical agents with high diffusion rates, may diffuse to a significant extent through the swollen polymer layer, causing premature release of the active into the oral thin film, and resulting in a bitter or otherwise unpleasant sensation during oral consumption.
  • a dual-coat method is used in which an ethylcelluose based coating solution (“under-coat”) is sprayed onto the core particle/granule containing the active.
  • under-coat an ethylcelluose based coating solution
  • top-coat is applied over the under-coat, the top coating being made from reverse-enteric polymer composition.
  • the ethylcellulose layer is relatively insoluble in water, does not swell appreciably, and creates a temporary moisture barrier against premature saliva penetration through the top coat.
  • the outer top-coat may swell as it absorbs water, but the water will be prevented from reaching the active due to the under-coat.
  • top-coat dissolves and the ethylcellulose under-coat is now completely exposed to water, which in turn causes release of the drug from the core.
  • the top-coat in this case may include similar additional non-pH dependent additives as described above.
  • the under-coat thus acts as a temporary moisture barrier during the time the coated particles are sitting in the aqueous neutral environment, e.g., during manufacturing or while residing in the mouth, to prevent leaching of the drug and concomitant unpleasant taste.
  • a scavenger or other complexing agent, for the active is incorporated into the top coat, under coat or granulated with the active.
  • Scavengers can attract actives, such as drug molecules and other charged species, and sequester them.
  • charged drug molecules may be attracted to the interstitial spaces of finely divided magnesium trisilicate. In this manner, the drug is removed or scavenged from the aqueous environment, thereby reducing or eliminating the possibility of the user tasting the drug.
  • Other absorbate materials may also be used.
  • materials such as cyclodextrin, which can form inclusion complexes with drug members and other actives may also be employed.
  • Such scavengers, absorbates and other similar agents may be employed in taste- masking effecting amounts.
  • the amount of scavenger, absorbates or other similar agents may be dependent to the amount of free drug expected in the resulting film. For example, in some embodiments, they may be present in the range of about 1 : 10 to about 10: 1 by weight of the free drug present in the film. In other embodiments, they may be present in the range of about 1 :5 to about 5 : 1 by weight of the free drug present in the film. In other
  • they may be present in the range of about 1 :3 to about 3 : 1 by weight of the free drug present in the film. In some embodiments, they may be present in a 1 : 1 ratio with the free drug present in the film.
  • Anti-foaming and/or de-foaming components may also be used with the films. These components aid in the removal of air, such as entrapped air, from the film- forming compositions. Such entrapped air may lead to non-uniform films. Simethicone is one particularly useful anti-foaming and/or de-foaming agent. The present invention, however, is not so limited and other suitable anti-foam and/or de-foaming agents may be used.
  • simethicone and related agents may be employed for densification purposes. More specifically, such agents may facilitate the removal of voids, air, moisture, and similar undesired components, thereby providing denser, and thus more uniform films. Agents or components which perform this function can be referred to as densification or densifying agents. As described above, entrapped air or undesired components may lead to non-uniform films.
  • Simethicone is generally used in the medical field as a treatment for gas or colic in babies.
  • Simethicone is a mixture of fully methylated linear siloxane polymers containing repeating units of polydimethylsiloxane which is stabilized with trimethylsiloxy end-blocking unites, and silicon dioxide. It usually contains 90.5-99% polymethylsiloxane and 4-7% silicon dioxide. The mixture is a gray, translucent, viscous fluid which is insoluble in water.
  • the mixing step may be performed under vacuum. However, as soon as the mixing step is completed, and the film solution is returned to the normal atmosphere condition, air will be re -introduced into or contacted with the mixture. In many cases, tiny air bubbles will be again trapped inside this polymeric viscous solution.
  • the incorporation of simethicone into the film-forming composition either substantially reduces or eliminates the formation of air bubbles during and after mixing.
  • the wet casting manufacturing process of oral thin films requires that the actives are suspended in an aqueous solution or solvent for at least a minute. In some instances, the actives are suspended in the aqueous solution or solvent for at least two hours. Inclusion of bitter or bad-tasting active pharmaceutical agents in oral thin film requires that a coating be applied to the active to prevent the consumer from experiencing bad taste. This coating acts as a barrier that prevents access of a solvent, such as water, to the active. In addition, the barrier must be practically water-insoluble at neutral pH conditions.
  • Aqueous polymer solutions employed in the invention may be formulated to have a pH greater than 6. In some instances, the aqueous polymer solution may be formulated to have pH of between about 5 and about 9.
  • optional components and fillers also may be added to the films. These may include, without limitation: surfactants; plasticizers; polyalcohols; anti-foaming agents, such as silicone-containing compounds, which promote a smoother film surface by releasing oxygen from the film; thermo-setting gels such as pectin, carageenan, and gelatin, which help in maintaining the dispersion of components; inclusion compounds, such as cyclodextrins and caged molecules; coloring agents; and flavors. In some embodiments, more than one active component may be included in the film.
  • Additives may be included in the films.
  • classes of additives include excipients, lubricants, buffering agents, stabilizers, blowing agents, pigments, coloring agents, fillers, bulking agents, sweetening agents, flavoring agents, fragrances, release modifiers, adjuvants, plasticizers, flow accelerators, mold release agents, polyols, granulating agents, diluents, binders, buffers, absorbents, glidants, adhesives, anti-adherents, acidulants, softeners, resins, demulcents, solvents, surfactants, emulsifiers, elastomers and mixtures thereof. These additives may be added with the active agent(s).
  • Useful additives include, for example, gelatin, vegetable proteins such as sunflower protein, soybean proteins, cotton seed proteins, peanut proteins, grape seed proteins, whey proteins, whey protein isolates, blood proteins, egg proteins, acrylated proteins, water-soluble polysaccharides such as alginates, carrageenans, guar gum, agar-agar, xanthan gum, gellan gum, gum arabic and related gums (gum ghatti, gum karaya, gum tragancanth), pectin, water- soluble derivatives of cellulose: alkylcelluloses hydroxyalkylcelluloses and
  • hydroxyalkylalkylcelluloses such as methylcellulose, hydroxymethylcellulose,
  • hydroxyalkylcellulose esters such as cellulose acetate phthalate (CAP),
  • HPMC hydroxypropylmethylcellulose
  • carboxyalkylcelluloses
  • carboxyalkylalkylcelluloses such as carboxymethylcellulose and their alkali metal salts
  • water-soluble synthetic polymers such as polyacrylic acids and polyacrylic acid esters, polymethacrylic acids and polymethacrylic acid esters,
  • PVAP polyvinylacetates, polyvinylalcohols, polyvinylacetatephthalates
  • polyvinylpyrrolidone PVY/vinyl acetate copolymer, and polycrotonic acids
  • phthalated gelatin gelatin succinate, crosslinked gelatin, shellac, water-soluble chemical derivatives of starch, cationically modified acrylates and methacrylates possessing, for example, a tertiary or quaternary amino group, such as the diethylaminoethyl group, which may be quaternized if desired; and other similar polymers.
  • Such extenders may optionally be added in any desired amount desirably within the range of up to about 80%, desirably about 3% to 50%> and more desirably within the range of 3% to 20% based on the weight of all film components.
  • Further additives may be inorganic fillers, such as the oxides of magnesium aluminum, silicon, titanium, etc. desirably in a concentration range of about 0.02% to about 3%) by weight and desirably about 0.02%> to about 1% based on the weight of all film components.
  • additives are plasticizers which include polyalkylene oxides, such as polyethylene glycols, polypropylene glycols, polyethylene-propylene glycols, organic plasticizers with low molecular weights, such as glycerol, glycerol monoacetate, diacetate or triacetate, triacetin, polysorbate, cetyl alcohol, propylene glycol, sorbitol, sodium
  • diethylsulfosuccinate, triethyl citrate, tributyl citrate, and the like added in concentrations ranging from about 0.5% to about 30%, and desirably ranging from about 0.5% to about 20% based on the weight of the polymer.
  • starch material may further be added compounds to improve the flow properties of the starch material such as animal or vegetable fats, desirably in their hydrogenated form, especially those which are solid at room temperature.
  • animal or vegetable fats desirably have a melting point of 50°C or higher.
  • tri-glycerides with C 12 -, C 14 -, C 16 -, C 18 -, C 2 o- and C 22 - fatty acids. These fats can be added alone without adding extenders or plasticizers and can be
  • the mono- and di-glycerides are desirably derived from the types of fats described above, i.e. with C 12 -, C 14 -, C 16 -, C 18 -, C 2 o- and C 22 - fatty acids.
  • the total amounts used of the fats, mono-, di-glycerides and/or lecithins may be up to about 5% and preferably within the range of about 0.5% to about 2% by weight of the total film composition.
  • Lecithin is one surface active agent for use in the films described herein. Lecithin may be included in the feedstock in an amount of from about 0.25% to about 2.00% by weight.
  • Other surface active agents i.e. surfactants, include, but are not limited to, cetyl alcohol, sodium lauryl sulfate, the SpansTM and TweensTM which are commercially available from ICI Americas, Inc.
  • Ethoxylated oils including ethoxylated castor oils, such as
  • Cremophor® EL which is commercially available from BASF, are also useful.
  • CarbowaxTM is yet another modifier which is very useful in the present invention.
  • TweensTM or combinations of surface active agents may be used to achieve the desired hydrophilic- lipophilic balance (“HLB").
  • binders which contribute to the ease of formation and general quality of the films.
  • Non- limiting examples of binders include starches, pregelatinize starches, gelatin, polyvinylpyrrolidone, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, and polyvinylalcohols.
  • the film may include other additives, such as keratin, or proteins, including proteins that are useful in forming a gel, such as gelatine.
  • Such agents include solubility enhancing agents, such as substances that form inclusion compounds with active components. Such agents may be useful in improving the properties of very insoluble and/or unstable actives.
  • these substances are doughnut-shaped molecules with hydrophobic internal cavities and hydrophilic exteriors. Insoluble and/or instable actives may fit within the hydrophobic cavity, thereby producing an inclusion complex, which is soluble in water. Accordingly, the formation of the inclusion complex permits very insoluble and/or instable actives to be dissolved in water.
  • a particularly desirable example of such agents are cyclodextrins, which are cyclic carbohydrates derived from starch. Other similar substances, however, are considered well within the scope of the present invention.
  • Suitable coloring agents include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), or external drug and cosmetic colors (Ext. D&C). These colors are dyes, their corresponding lakes, and certain natural and derived colorants. Lakes are dyes absorbed on aluminum hydroxide. Other examples of coloring agents include known azo dyes, organic or inorganic pigments, or coloring agents of natural origin. Inorganic pigments are preferred, such as the oxides of iron or titanium, these oxides, being added in concentrations ranging from about 0.001 to about 10%, and preferably about 0.5 to about 3%, based on the weight of all the components.
  • Flavors may be chosen from natural and synthetic flavoring liquids.
  • An illustrative list of such agents includes volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof.
  • a non-limiting representative list of examples includes mint oils, cocoa, and citrus oils such as lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot or other fruit flavors.
  • aldehydes and esters such as benzaldehyde (cherry, almond), citral i.e., alphacitral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldehyde C-9 (citrus fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanol (green fruit), and 2- dodecenal (citrus, mandarin), d-Limonene (citrus), Dimethyl anthranilate (grape)
  • aldehydes and esters such as benzaldehyde (cherry, almond), citral i.e., alphacitral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon
  • the sweeteners may be chosen from the following non-limiting list: glucose (corn syrup), dextrose, invert sugar, fructose, and combinations thereof; saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, xylitol, and the like. Also, glucose (corn syrup), dextrose, invert sugar, fructose, and combinations thereof; saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, xylit
  • contemplated are hydrogenated starch hydro lysates and the synthetic sweetener 3,6-dihydro- 6-methyl-l-l-l,2,3-oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (acesulfame- K), and sodium and calcium salts thereof, and natural intensive sweeteners, such as Lo Han Kuo. Other sweeteners may also be used.
  • the synthetic sweetener 3,6-dihydro- 6-methyl-l-l-l,2,3-oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (acesulfame- K), and sodium and calcium salts thereof, and natural intensive sweeteners, such as Lo Han Kuo. Other sweeteners may also be used.
  • Example 1 Composition of a dual coat particle
  • the components of the dual coat film are listed in Table 1 along with the percentages of each component by weight of the coated active particle.
  • the components of the film dosage unit are listed in Table 2 along with the percentages of each component by weight of the coated active particle.
  • a coherent, accurate coated particle is produced which is placed into a polymer matrix to form individual film dosage units which dissolves substantially instantaneously in the oral cavity, releasing all components substantially simultaneously.
  • the coated active composition will remain coated until it reaches pH level of approximately 4 and thus is substantially undetectable in the oral cavity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une forme pharmaceutique de film comestible qui comprend un polymère filmogène et une composition active enrobée capable de masquer le goût d'un principe actif contenu à l'intérieur. L'invention porte en outre sur un film comestible qui comprend un polymère filmogène comestible hydrosoluble et un principe actif muni d'au moins deux couches d'enrobage.
PCT/US2010/059851 2009-12-10 2010-12-10 Composés sensibles au ph destinés à masquer le goût de bandelettes orales sous forme de film mince Ceased WO2011072208A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2783877A CA2783877A1 (fr) 2009-12-10 2010-12-10 Composes sensibles au ph destines a masquer le gout de bandelettes orales sous forme de film mince
CN2010800634577A CN102753196A (zh) 2009-12-10 2010-12-10 口服薄膜条内掩味的pH敏感性化合物
EP10836740.0A EP2509631A4 (fr) 2009-12-10 2010-12-10 Composés sensibles au ph destinés à masquer le goût de bandelettes orales sous forme de film mince

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28530109P 2009-12-10 2009-12-10
US61/285,301 2009-12-10

Publications (1)

Publication Number Publication Date
WO2011072208A1 true WO2011072208A1 (fr) 2011-06-16

Family

ID=44143220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/059851 Ceased WO2011072208A1 (fr) 2009-12-10 2010-12-10 Composés sensibles au ph destinés à masquer le goût de bandelettes orales sous forme de film mince

Country Status (5)

Country Link
US (1) US20110142942A1 (fr)
EP (1) EP2509631A4 (fr)
CN (1) CN102753196A (fr)
CA (1) CA2783877A1 (fr)
WO (1) WO2011072208A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10668019B2 (en) 2014-11-30 2020-06-02 Kirit Patel Process for preparation of a drug-polymer composition
US11844763B2 (en) 2014-04-17 2023-12-19 Avenir Wellness Solutions, Inc. Pharmaceutical composition and method of manufacturing
US11890310B2 (en) 2014-04-17 2024-02-06 Avenir Wellness Solutions, Inc. Pharmaceutical composition and method of manufacturing

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
KR101328162B1 (ko) * 2011-06-27 2013-11-13 조선대학교산학협력단 생분해 고분자 소재를 이용한 테입형 불소제제 및 이의 제조방법
US9539334B2 (en) * 2012-05-17 2017-01-10 John Hopkins University Orally dissolving thin films containing allergens and methods of making and use
MX352308B (es) * 2012-12-14 2017-11-17 Colgate Palmolive Co Películas abrasibles para uso en cuidado oral.
KR101643572B1 (ko) * 2013-03-07 2016-07-29 에스케이케미칼주식회사 고함량의 약물을 함유하는 구강 붕해 필름 및 이의 제조방법
MX2016007786A (es) * 2013-12-16 2017-03-03 Massachusetts Inst Technology Formulaciones de sal de micronutrientes fortificadas.
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US10632113B2 (en) 2014-02-05 2020-04-28 Kashiv Biosciences, Llc Abuse-resistant drug formulations with built-in overdose protection
EP3122336A4 (fr) * 2014-03-26 2017-10-25 Sun Pharma Advanced Research Company Ltd Forme galénique solide de matrice biphasique à libération immédiate et dissuasive d'abus
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
US12150967B2 (en) 2018-08-18 2024-11-26 Seed Health, Inc. Methods and compositions for honey bee health

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489436A (en) * 1991-06-14 1996-02-06 Mcneil-Ppc, Inc. Taste mask coatings for preparation of chewable pharmaceutical tablets
US6482517B1 (en) * 1997-09-09 2002-11-19 Select Release, L.C. Coated particles, methods of making and using
US20050136115A1 (en) * 2003-12-15 2005-06-23 Council Of Scientific And Industrial Research Taste masked pharmaceutical composition comprising pH sensitive polymer
US20060182796A1 (en) * 2005-02-03 2006-08-17 Abrika Pharmaceuticals, Inc. Taste masked pharmaceutical compositions
US20070098746A1 (en) * 2005-11-02 2007-05-03 Nichols William M Multi-layered coating technology for taste masking
US20080044454A1 (en) * 2002-04-11 2008-02-21 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20090196907A1 (en) * 2008-01-31 2009-08-06 Bunick Frank J Edible film-strips for immediate release of active ingredients

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33093E (en) * 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
DE3900811A1 (de) * 1989-01-13 1990-07-19 Kali Chemie Pharma Gmbh Neue arzneiform
JPH03232817A (ja) * 1990-02-07 1991-10-16 Showa Yakuhin Kako Kk 貼付剤
DE4018247A1 (de) * 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
CA2304630A1 (fr) * 1997-10-03 1999-04-15 Elan Corporation, Plc Preparation au gout dissimule
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6270790B1 (en) * 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
EP1169024B1 (fr) * 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Amidon pregelatinise dans une formulation a liberation regulee
US6482823B1 (en) * 1999-07-09 2002-11-19 Ortho-Mcneil Pharmaceutical, Inc. Taste masked pharmaceutical liquid formulations
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
WO2001080826A2 (fr) * 2000-04-20 2001-11-01 Bristol-Myers Squibb Company Composition d'enrobage masquant le gout
US7425292B2 (en) * 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7659253B2 (en) * 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
WO2005040228A2 (fr) * 2003-10-24 2005-05-06 Adhesives Research, Inc. Films disintegrables destines a des dispositifs de diagnostic
WO2007030754A2 (fr) * 2005-09-09 2007-03-15 Monosolrx, Llc Films uniformes pour dosage posologique a dissolution rapide comprenant des compositions antiadherentes
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
US20080233174A1 (en) * 2007-01-12 2008-09-25 Monosol Rx, Llc High dose film compositions and methods of preparation
EP2227226B1 (fr) * 2007-12-21 2016-10-26 Johnson & Johnson Consumer Inc. Fabrication d'un comprimé
WO2009099831A2 (fr) * 2008-01-31 2009-08-13 Mcneil-Ppc, Inc. Bandes de film comestible à libération modifiée d’ingrédients actifs
US20100285130A1 (en) * 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489436A (en) * 1991-06-14 1996-02-06 Mcneil-Ppc, Inc. Taste mask coatings for preparation of chewable pharmaceutical tablets
US6482517B1 (en) * 1997-09-09 2002-11-19 Select Release, L.C. Coated particles, methods of making and using
US20080044454A1 (en) * 2002-04-11 2008-02-21 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20050136115A1 (en) * 2003-12-15 2005-06-23 Council Of Scientific And Industrial Research Taste masked pharmaceutical composition comprising pH sensitive polymer
US20060182796A1 (en) * 2005-02-03 2006-08-17 Abrika Pharmaceuticals, Inc. Taste masked pharmaceutical compositions
US20070098746A1 (en) * 2005-11-02 2007-05-03 Nichols William M Multi-layered coating technology for taste masking
US20090196907A1 (en) * 2008-01-31 2009-08-06 Bunick Frank J Edible film-strips for immediate release of active ingredients

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2509631A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844763B2 (en) 2014-04-17 2023-12-19 Avenir Wellness Solutions, Inc. Pharmaceutical composition and method of manufacturing
US11890310B2 (en) 2014-04-17 2024-02-06 Avenir Wellness Solutions, Inc. Pharmaceutical composition and method of manufacturing
US11938160B2 (en) 2014-04-17 2024-03-26 Avenir Wellness Solutions, Inc. Pharmaceutical composition and method of manufacturing
US10668019B2 (en) 2014-11-30 2020-06-02 Kirit Patel Process for preparation of a drug-polymer composition

Also Published As

Publication number Publication date
EP2509631A4 (fr) 2014-04-02
CN102753196A (zh) 2012-10-24
CA2783877A1 (fr) 2011-06-16
EP2509631A1 (fr) 2012-10-17
US20110142942A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
US20110142942A1 (en) USE OF pH SENSITIVE COMPOUNDS IN TASTE MASKING OF DRUG SUBSTANCES WITHIN ORAL THIN FILM STRIPS
AU2020200651B2 (en) Sublingual and buccal film compositions
CA2770180C (fr) Compositions pelliculaires sublinguales et buccales
DK2968121T3 (en) SUBLINGUAL AND BUCHAL FILM COMPOSITIONS
CA2701484A1 (fr) Compositions de pellicules d'ondansetron
US20100285130A1 (en) Coating of complexed actives in film formulations
US20160114043A1 (en) Stabilized Amine-Containing Actives in Oral Film Compositions
HK1171960B (en) Sublingual and buccal film compositions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080063457.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10836740

Country of ref document: EP

Kind code of ref document: A1

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10836740

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2783877

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 5666/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010836740

Country of ref document: EP